Business
Aethlon Medical Announces Issuance of Hemopurifier® Patents for the Treatment of Long COVID and COVID-19-associated Coagulopathy (CAC)
Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD) announced that U.S. Patent No. 12,409,260 (the "260 Patent") directed to treatment of Long COVID will issue on September 9, 2025, and Unitary European Patent 4136453 (the "453 Patent") directed to the treatment of COVID-19-associated coagulopathy ("CAC") issued July 9, 2025.
About this update from Aethlon Medical, Inc.
[{"type":"text","content":"SAN DIEGO, Sept. 3, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD) announced that U.S. Patent No. 12,409,260 (the "260 Patent") directed to treatment of Long COVID will issue on September 9, 2025, and Unitary European Patent 4136453 (the "453 Patent") directed to the treatment of COVID-19-associated coagulopathy ("CAC") issued July 9, 2025.","length":432,"tagName":"p"},{"type":"text","content":"The 260 Patent is intended to protect the use of the Hemopurifier® in the United States to treat patients that have a reduced COVID-19 viral load but exhibit Long COVID symptoms for more than 12 weeks post infection. The 260 Patent additionally protects the treatment of patients experiencing Long COVID symptoms by the removal of circulating COVID-19 spike protein.","length":366,"tagName":"p"},{"type":"text","content":"The 453 Patent is intended to protect the use of the Hemopurifier® for the treatment of patients that lack circulating COVID-19 viral particles but exhibit COVID-19-associated CAC.","length":180,"tagName":"p"},{"type":"text","content":"The 260 Patent was granted an additional 385 days of patent term due to patent term adjustment and will expire in 2042. The 453 Patent will expire in 2041.","length":155,"tagName":"p"},{"type":"text","content":""We believe securing these patents expands and strengthens our intellectual property portfolio in areas of significant unmet medical need," said James Frakes, CEO and CFO of Aethlon. "While the Hemopurifier® remains in the research and development stage relating to Long COVID, these protections position us well as we continue advancing potential future applications. Our goal is to build a strong foundation of innovation that could one day translate into meaningful treatment options for patients."","length":521,"tagName":"p"},{"type":"text","content":"About the Hemopurifier®","length":23,"tagName":"p"},{"type":"text","content":"The Aethlon Hemopurifier® is an investigational medical device designed to remove enveloped viruses, fragments of viruses, and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich su...